{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Film", "query": { "intervention": "Placebo Film" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 305, "total_pages": 31, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Film&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T20:27:56.816Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06192615", "title": "Minimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep (MINDDS II)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Delirium" ], "interventions": [ { "name": "Intravenous Dexmedetomidine", "type": "DRUG" }, { "name": "Sublingual Dexmedetomidine", "type": "DRUG" }, { "name": "Intravenous Placebo", "type": "DRUG" }, { "name": "Sublingual Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 1800, "start_date": "2025-01-06", "completion_date": "2029-03-31", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-09-04T20:27:56.816Z", "location_count": 14, "location_summary": "Los Angeles, California • San Francisco, California • Chicago, Illinois + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06192615" }, { "nct_id": "NCT06125951", "title": "Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Dementia Moderate", "Dementia, Mild", "Alzheimer Disease" ], "interventions": [ { "name": "Xanamem", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Actinogen Medical", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 247, "start_date": "2024-04-12", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-09-04T20:27:56.816Z", "location_count": 19, "location_summary": "Carlsbad, California • Sherman Oaks, California • Denver, Colorado + 16 more", "locations": [ { "city": "Carlsbad", "state": "California" }, { "city": "Sherman Oaks", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Englewood", "state": "Colorado" }, { "city": "Delray Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06125951" }, { "nct_id": "NCT04010305", "title": "Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Agitation", "Schizophrenia" ], "interventions": [ { "name": "Sublingual film containing BXCL501 (Dexmedetomidine)", "type": "DRUG" }, { "name": "Placebo film", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioXcel Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 135, "start_date": "2019-05-22", "completion_date": "2019-07-31", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-09-04T20:27:56.816Z", "location_count": 12, "location_summary": "Little Rock, Arkansas • Cerritos, California • Lemon Grove, California + 9 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Cerritos", "state": "California" }, { "city": "Lemon Grove", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04010305" }, { "nct_id": "NCT05650567", "title": "Study of M5049 in DM and PM Participants (NEPTUNIA)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dermatomyositis", "Polymyositis" ], "interventions": [ { "name": "M5049 high dose", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 40, "start_date": "2023-01-19", "completion_date": "2025-06-25", "has_results": false, "last_update_posted_date": "2025-07-17", "last_synced_at": "2026-09-04T20:27:56.816Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05650567" }, { "nct_id": "NCT02415400", "title": "A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Acute Coronary Syndromes" ], "interventions": [ { "name": "Apixaban", "type": "DRUG" }, { "name": "vitamin K antagonist", "type": "DRUG" }, { "name": "Acetylsalicylic acid", "type": "DRUG" }, { "name": "Acetylsalicylic acid placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "95 Years", "sex": "ALL", "summary": "18 Years to 95 Years" }, "enrollment_count": 4614, "start_date": "2015-06-04", "completion_date": "2018-11-10", "has_results": true, "last_update_posted_date": "2020-06-11", "last_synced_at": "2026-09-04T20:27:56.816Z", "location_count": 143, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 125 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02415400" }, { "nct_id": "NCT01675167", "title": "Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Experienced Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Low Back Pain" ], "interventions": [ { "name": "Buprenorphine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioDelivery Sciences International", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 815, "start_date": "2012-09", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2017-02-27", "last_synced_at": "2026-09-04T20:27:56.816Z", "location_count": 66, "location_summary": "Birmingham, Alabama • Haleyville, Alabama • Mobile, Alabama + 57 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Haleyville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01675167" }, { "nct_id": "NCT03409107", "title": "Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anaemia" ], "interventions": [ { "name": "Daprodustat (GSK1278863)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Iron therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 614, "start_date": "2018-03-05", "completion_date": "2020-10-07", "has_results": true, "last_update_posted_date": "2024-04-02", "last_synced_at": "2026-09-04T20:27:56.816Z", "location_count": 49, "location_summary": "Homewood, Alabama • Little Rock, Arkansas • Downey, California + 44 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Lynwood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03409107" }, { "nct_id": "NCT03234036", "title": "A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infection, Human Immunodeficiency Virus", "HIV Infections" ], "interventions": [ { "name": "GSK2838232 100 mg tablet", "type": "DRUG" }, { "name": "GSK2838232 50 mg capsule", "type": "DRUG" }, { "name": "Ritonavir 100 mg tablets", "type": "DRUG" }, { "name": "Placebo for GSK2838232 tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 26, "start_date": "2017-08-02", "completion_date": "2017-11-10", "has_results": true, "last_update_posted_date": "2020-10-28", "last_synced_at": "2026-09-04T20:27:56.816Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03234036" }, { "nct_id": "NCT03555422", "title": "Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endometrial Cancer" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Matching placebo for selinexor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Karyopharm Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 263, "start_date": "2018-01-05", "completion_date": "2025-04-03", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-09-04T20:27:56.816Z", "location_count": 19, "location_summary": "Tucson, Arizona • Palo Alto, California • Tampa, Florida + 14 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Oak Lawn", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03555422" }, { "nct_id": "NCT05025605", "title": "Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia", "Schizo-Affective Disorder", "Schizophreniform; Schizophrenic", "Bipolar Disorder I", "Bipolar Disorder II" ], "interventions": [ { "name": "BXCL501 80 Micrograms", "type": "DRUG" }, { "name": "Placebo Film", "type": "DRUG" }, { "name": "BXCL501 120 Micrograms", "type": "DRUG" }, { "name": "BXCL501 60 Micrograms", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioXcel Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "10 Years to 17 Years" }, "enrollment_count": 140, "start_date": "2021-08-27", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-09-04T20:27:56.816Z", "location_count": 5, "location_summary": "Anaheim, California • Hialeah, Florida • Atlanta, Georgia + 2 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Decatur", "state": "Georgia" }, { "city": "DeSoto", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05025605" } ] }